Unicycive Therapeutics amends reverse stock split ratio range to 1-for-2 to 1-for-20

Unicycive Therapeutics, Inc.

Amendment No. 1 changes the reverse stock split ratio range from 1-for-10–1-for-20 to 1-for-2–1-for-20.
The amendment modifies Section 4.16(iii) of the Securities Purchase Agreement dated March 3, 2023.
Company will seek stockholder approval of the revised reverse split range at the upcoming annual meeting.

item 1.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Unicycive Therapeutics, Inc. amended Amendment No. 1 with the investors named therein (effective 2023-04-06).

Action: amendment
Agreement: equity purchase
Counterparty: the investors named therein
Effective: 2023-04-06

Exact text from the filing

On April 6, 2023, Unicycive Therapeutics, Inc. (the “Company”) entered into Amendment No. 1 to the Securities Purchase Agreement originally dated as of March 3, 2023 (‘Amendment No. 1”) pursuant to which the Company and the investors named therein agreed that, with respect to the upcoming annual meeting of stockholders, the Company would be seeking stockholder approval of a reverse stock split of its common stock at a specific ratio within a range of 1-for-2 to 1-for-20 rather than 1-for-10 to 1-for-20.

View on SEC.gov

623 material agreements filed in the last 30 days. Browse all material agreements →

Unicycive Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-23-028383

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.